Amplia Therapeutics Ltd (ASX:ATX)'s chief scientific officer Mark Devlin speaks to Proactive following the news it's completed a review of all primary, secondary and exploratory endpoints in its phase 1 clinical trial of AMP945. He says the results confirm that AMP945 was safe and well tolerated at all doses tested, exhibited excellent pharmacokinetic properties and was able to engage with its intended target, Focal Adhesion Kinase (FAK).
Amplia Therapeutics details summary results from its phase 1 clinical trial of AMP945
